Erlonix

Adults:

NSCLC: The recommended daily dose of Erlotinib for NSCLC is 150 mg, taken on an empty stomach, that is, at least one hour before or two hours after eating. Treatment should continue until the disease progresses or unacceptable toxicity occurs. Pancreatic Cancer: The recommended daily dose of Erlotinib for pancreatic cancer is 100 mg, taken once daily in combination with gemcitabine. Take Erlotinib on an empty stomach, that is, at least one hour before or two hours after eating. Treatment should continue until the disease progresses or unacceptable toxicity occurs. Reduce Erlotinib in 50 mg decrements if severe reactions occur with concomitant use of strong CYP3A4 inhibitors (such as atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, or grapefruit or grapefruit juice) or when used concomitantly with an inhibitor of both CYP3A4 and CYP1A2 (for example, ciprofloxacin). Increase Erlotinib in 50 mg increments as tolerated for concomitant use with CYP3A4 inducers, such as rifampin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, or St. John's Wort. Increase doses in 50 mg increments at 2 week intervals to a maximum of 450 mg. Avoid concomitant use if possible. Concurrent cigarette smoking: Increase in 50 mg increments at 2 week intervals to a maximum of 300 mg. Immediately reduce the dose of Erlotinib to the recommended dose (150 mg or 100 mg daily) upon cessation of smoking.